1. Home
  2. PBYI vs CURR Comparison

PBYI vs CURR Comparison

Compare PBYI & CURR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBYI
  • CURR
  • Stock Information
  • Founded
  • PBYI 2010
  • CURR 2013
  • Country
  • PBYI United States
  • CURR Singapore
  • Employees
  • PBYI N/A
  • CURR N/A
  • Industry
  • PBYI Biotechnology: Pharmaceutical Preparations
  • CURR Business Services
  • Sector
  • PBYI Health Care
  • CURR Consumer Discretionary
  • Exchange
  • PBYI Nasdaq
  • CURR Nasdaq
  • Market Cap
  • PBYI 153.2M
  • CURR 133.1M
  • IPO Year
  • PBYI N/A
  • CURR N/A
  • Fundamental
  • Price
  • PBYI $2.97
  • CURR $2.22
  • Analyst Decision
  • PBYI Strong Buy
  • CURR
  • Analyst Count
  • PBYI 1
  • CURR 0
  • Target Price
  • PBYI $7.00
  • CURR N/A
  • AVG Volume (30 Days)
  • PBYI 821.3K
  • CURR 16.5M
  • Earning Date
  • PBYI 02-27-2025
  • CURR 02-11-2025
  • Dividend Yield
  • PBYI N/A
  • CURR N/A
  • EPS Growth
  • PBYI 492.79
  • CURR N/A
  • EPS
  • PBYI 0.47
  • CURR N/A
  • Revenue
  • PBYI $243,569,000.00
  • CURR $48,723,898.00
  • Revenue This Year
  • PBYI N/A
  • CURR N/A
  • Revenue Next Year
  • PBYI N/A
  • CURR N/A
  • P/E Ratio
  • PBYI $6.38
  • CURR N/A
  • Revenue Growth
  • PBYI 6.30
  • CURR N/A
  • 52 Week Low
  • PBYI $2.23
  • CURR $1.19
  • 52 Week High
  • PBYI $7.73
  • CURR $7.08
  • Technical
  • Relative Strength Index (RSI)
  • PBYI 45.95
  • CURR N/A
  • Support Level
  • PBYI $2.92
  • CURR N/A
  • Resistance Level
  • PBYI $4.06
  • CURR N/A
  • Average True Range (ATR)
  • PBYI 0.27
  • CURR 0.00
  • MACD
  • PBYI -0.03
  • CURR 0.00
  • Stochastic Oscillator
  • PBYI 4.39
  • CURR 0.00

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

About CURR Currenc Group Inc. Ordinary Shares

Currenc Group Inc is a fintech banking platform for e-wallets, financial institutions and merchants world-wide, delivering frictionless interoperable real-time fund transfers and instant messaging.

Share on Social Networks: